Toulouse

• Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting
  2024-511871-13-00 6 2025-10-02 Postmenopausal osteoporosis
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting
  2024-511989-36-00 5 2025-09-24 Ewing Sarcoma
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 4 2025-07-31 High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
• Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting
  2024-519521-37-01 10 2025-07-30 Acute ischemic stroke
• An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resistant generalized myasthenia gravis Recruiting
  2024-513589-20-00 9 2025-07-29 Treatment-resistant generalized Myasthenia Gravis
• A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s … Recruiting
  2024-513682-40-01 5 2025-07-04 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
• A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting
  2024-519248-34-00 4 2025-06-17 Cervical Dystonia
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 6 2025-06-16 Rheumatoid arthritis
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis
• A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior … Recruiting
  2024-513112-99-00 5 2025-06-13 Active Psoriatic Arthritis Stratified by Prior Biologic Use
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient … Recruiting
  2023-510026-32-00 5 2025-06-11 Generalized Myasthenia Gravis
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• Blocage de l'interféron-ɣ par le ruxolitinib pour le traitement de la myosite à inclusion : un essai de phase IIb Recruiting
  2023-507666-32-00 4 2025-05-27 Inclusion body Myositis
• A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla … Recruiting
  2024-514341-10-00 1 2025-05-27 Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re … Recruiting
  2024-516650-22-00 6 2025-05-16 Renal carcinoma
• Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting
  2023-508634-34-00 4 2025-05-14 co-infected with the HIV-1 and HBV viruses

Showing 193–216 of 653 trials